Pyrotinib in Women With High-risk in Early Stage Breast Cancer

This study is testing pyrotinib — a targeted oral drug that blocks HER2 and related proteins — as an additional treatment for people with HER2-positive early breast cancer who still had remaining cancer after standard pre-surgery chemo plus trastuzumab/pertuzumab (or T-DM1). These are patients considered high risk because their cancer did not fully disappear with standard therapy. **You may be eligible if...** - You have HER2-positive early or locally advanced breast cancer confirmed by biopsy - Your cancer did not completely disappear after standard pre-surgery treatment (no pathologic complete response) - You had lymph node involvement after surgery - You have already completed standard trastuzumab-based treatment - You are 18–75 years old with good overall health **You may NOT be eligible if...** - Your cancer has spread to other parts of the body (stage IV or inflammatory breast cancer) - You have had another cancer in the past - You have serious heart disease or uncontrolled high blood pressure - You have significant gastrointestinal disease that causes chronic diarrhea - You are unable to swallow tablets Talk to your doctor to see if this trial is right for you.